Biofrontera Bioscience GmbH
6Patents
5Active
6Granted
48Portfolio score
Filing activity: Oct 25, 2002 → Dec 8, 2023 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7060711B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Chemistry; Metallurgy | 11 | Expired |
| US11540981B2 | Nanoemulsion formulation with improved stability and cell penetration | Human Necessities | 2 | Active |
| US12280146B2 | Nanoemulsion without propylene glycol | Human Necessities | 0 | Active |
| US11642411B2 | Photodynamic therapy comprising two light exposures at different wavelengths | Human Necessities | 0 | Active |
| US9708304B2 | Salt polymorph of thioxanthene-9-ylidene-1-methyl piperidine acid addition salts as antimigraine compounds | Human Necessities | 0 | Active |
| US7511064B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.